Abstract
The risk of liver enzyme elevation (LEE) after different ritonavir-boosted protease inhibitors (PI/r) has not been fully assessed in real-life settings and in populations with high rates of hepatitis C virus (HCV) coinfection.
| Original language | English |
|---|---|
| Pages (from-to) | 312-318 |
| Number of pages | 7 |
| Journal | Journal of Acquired Immune Deficiency Syndromes |
| Volume | 69 |
| DOIs | |
| Publication status | Published - 2015 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Adult
- Anti-HIV Agents
- Cohort Studies
- Drug Therapy, Combination
- Female
- HIV Infections
- Hepatitis B
- Hepatitis C
- Humans
- Italy
- Liver
- Male
- Middle Aged
- Protease Inhibitors
- Risk Factors
- Ritonavir
Fingerprint
Dive into the research topics of 'Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver